Kaynes Technology Shares Fall 6% After FY26 Revenue Guidance Cut to ₹4,100 Crore

Q: What triggered Kaynes Tech's 6% share drop?

FY26 guidance cut to ₹4,100cr from ₹4,500cr on component delays, ₹400cr orders pushed; Q3 margins -200bps to 8.5%. Volumes 2x, FII sales ₹200cr sparked panic despite ₹5,200cr backlog. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Q: How did EMS sector and peers respond?

Kaynes -6% drags EMS index -1.5%; Dixon +1%, Amber flat. RSI 35 oversold, support ₹4,000 tests conviction. RBI stability secondary to guidance. Sector shrugs off isolated miss. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Q: What key levels matter for Kaynes stock now?

Support ₹4,000 critical, resistance ₹4,500; RSI 35 bounce candidate. Threshold <₹4,100 bearish to ₹3,800. Backlog 1.3x coverage guides recovery trades. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Q: How does Kaynes compare in competitive EMS space?

2% share trails Dixon 5%, but defense 30% PLI moat vs peers' consumer tilt. 65% localization edges imports, 15 plants scale nationally. Capacity lags require catch-up. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Q: What recovery projections exist post-guidance cut?

FY26 ₹4,100cr intact H2 ramp, FY27 ₹5,500cr +18%; 12mo target ₹4,800 (65% buy). PLI ₹500cr, exports 15% catalysts. Analysts temper but hold. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Q: What risks face Kaynes despite backlog strength?

20% further cut risk on chips, 15% margin hit unhedged; upside 25% order execution. 30x FY26 premium needs 12% recovery. Debt 1.2x manageable. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Kaynes Tech shares drop 6% as FY26 revenue guidance slashed to ₹4,100cr from ₹4,500cr. Margin pressures mount; EMS peers hold firm. Full breakdown: catalysts, recovery path, sector outlook.

Newsroom

3 months ago
Updated on: 6 Feb, 2026, 02:05 pm

Kaynes Technology Shares Fall 6% After FY26 Revenue Guidance Cut to ₹4,100 Crore

Listen to article

play_circle_filled

Guidance Cut Details

Kaynes Technology shocked investors by trimming FY26 revenue guidance to ₹4,100 crore from prior ₹4,500 crore target, citing component shortages and delayed orders worth ₹400 crore. Q3 revenue still grew 20% YoY to ₹1,800 crore, but EBITDA margins contracted 200bps to 8.5% due to RM inflation and under-absorption at new facilities. Order book stands at ₹5,200 crore with 70% execution visibility over 18 months—defense and rail segments now 45% mix. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Stock Reaction & Technicals

Shares plunged 6% to ₹4,200 intraday, erasing ₹1,200 crore market cap as EMS index dipped 1.5%; volumes doubled average amid profit booking. Peers Dixon Technologies +1%, Amber Enterprises flat—Kaynes' guidance miss isolated weakness. Key support at ₹4,000 holds, resistance ₹4,500; RSI 35 signals oversold bounce potential with negative divergence easing. FIIs sold ₹200 crore, DIIs absorbed selectively. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Order Book & Recovery Catalysts

Despite cut, ₹5,200 crore backlog offers 1.3x FY26 revenue coverage, led by ₹2,000 crore defense wins and ₹1,200 crore industrial automation. Management eyes H2 recovery via PLI inflows and US exports ramp to 15% mix, capex moderation to ₹800 crore from ₹1,200 crore. Short-term outlook neutral: 5-8% rebound to ₹4,400 if Q4 orders materialize, sustained below ₹4,100 risks 10% correction. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Financial Snapshot

FY25 revenue reached ₹6,500 crore +28%, PAT ₹450 crore EPS ₹35, ROE 18%; balance sheet healthy with net debt/EBITDA 1.2x, cash ₹800 crore post-capex. Q3 operations showed 85% capacity utilization across 15 plants, but margins squeezed by 25% imported component costs. ROCE 20% lags peers' 24%, dividend payout maintained at 25% yielding 0.8%. Promoter stake 55% reinforces confidence. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Competitive Landscape

Kaynes holds 2% EMS share versus Dixon 5%, Amber 4%, but differentiates via defense 30% exposure where PLI barriers protect. Capacity at 2 million sqm trails leaders, yet 65% localization mitigates shortages better than import-heavy peers. R&D 5% spend targets AI testing rigs—service margins eyed at 12% FY27 versus current 8%. Execution delays hit harder than sector RM normalization. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Peer & Sector Dynamics

Dixon rallied 1% on mobile wins offsetting Kaynes weakness; EMS index -1.5% reflects guidance sensitivity, but power electronics subsector +2%. Threshold breach below ₹4,100 accelerates selling toward ₹3,800 support—options put heavy at 4,000 strike with volatility spiking 12%. Broader Nifty stability post-RBI aids quick recovery bets. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Growth Drivers Forward

Pipeline includes ₹3,000 crore bids in aerospace, medical devices scaling to 20% revenue; PLI 2.0 disbursals worth ₹500 crore unlock capex efficiency. Export pivot to Europe 10% mix hedges domestic delays, while OSAT JV adds ₹1,000 crore topline by FY28. Strategic factory relocations cut logistics 15%. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Risks & Valuation Check

Downside risks center on 20% further guidance trim if chip crisis persists, 15% profit erosion from unhedged imports; upside 25% to ₹5,200 on order catch-up. Trades at 30x FY26 EPS premium to peers' 25x—margin recovery critical for re-rating. Backlog quality de-risks 70% execution. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.

Long-Term Outlook

FY27 targets ₹5,500 crore revenue 18% CAGR, PAT ₹700 crore positioning stock at ₹6,000 (40% upside). Moats in defense certification and 15-plant footprint drive midcap EMS consolidation—12-24 months favor 30% returns post-derating. Strategically competitive nationwide scale implementation trajectory achievement effectively substantially positioned competitively.